請用此 Handle URI 來引用此文件: http://hdl.handle.net/11455/13888
標題: Pimobendan以及Enalapril對於犬隻二尖瓣疾病之影響
Effects of Pimobendan and Enalapril for Mitral Valve Disease in Dogs
作者: 麥元貞
Mai, Yuan- Jen
關鍵字: pimobendan
犬隻
enalapril
二尖瓣疾病
出版社: 獸醫學系暨研究所
引用: 參考文獻 Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. J Vet Intern Med 9: 234-42, 1995. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 66: 149-57, 2002. Bargiggia GS, Tronconi L, Sahn DJ, Recusani F, Raisaro A, De Servi S, Valdes-Cruz LM and Montemartini C. A new method for quantitation of mitral regurgitation based on color flow Doppler imaging of flow convergence proximal to regurgitant orifice. Circulation 84: 1481-9, 1991. Bohm M, Morano I, Pieske B, Ruegg JC, Wankerl M, Zimmermann R and Erdmann E. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689-701, 1991. Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, Bellino C, La Rosa G, Zanatta R, Haggstrom J and Tarducci A. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 22: 120-8, 2008. Brixius K, Hoyer HK and Schwinger RH. Ca2+-sensitisers--a promising option to treat heart failure? Cardiovasc Drugs Ther 19: 423-8, 2005. Brown NJ and Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 97: 1411-20, 1998. Chetboul V, Gouni V, Sampedrano CC, Tissier R, Serres F and Pouchelon JL. Assessment of regional systolic and diastolic myocardial function using tissue Doppler and strain imaging in dogs with dilated cardiomyopathy. J Vet Intern Med 21: 719-30, 2007. Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, Concordet D, Nicolle AP and Pouchelon JL. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med 21: 742-53, 2007. Chu KM, Hu OY and Shieh SM. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects. Drug Metab Dispos 27: 701-9, 1999. Curtiss C, Cohn JN, Vrobel T and Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58: 763-70, 1978. Dahlof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 9 Suppl 5: S37-44, 1995. Das KM and Tashjian RJ. Chronic mitral valve disease in the dog. Vet Med Small Anim Clin 60: 1209-16, 1965. Diwan A, McCulloch M, Lawrie GM, Reardon MJ and Nagueh SF. Doppler estimation of left ventricular filling pressures in patients with mitral valve disease. Circulation 111: 3281-9, 2005. Focaccio A, Volpe M, Ambrosio G, Lembo G, Pannain S, Rubattu S, Enea I, Pignalosa S and Chiariello M. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 87: 192-8, 1993. Gavras H, Faxon DP, Berkoben J, Brunner HR and Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58: 770-6, 1978. Gerber JG, Franca G, Byyny RL, LoVerde M and Nies AS. The hypotensive action of captopril and enalapril is not prostacyclin dependent. Clin Pharmacol Ther 54: 523-32, 1993. Gordon SG, Miller MW and Saunders AB. Pimobendan in heart failure therapy--a silver bullet? J Am Anim Hosp Assoc 42: 90-3, 2006. Guglielmini C, Diana A, Pietra M, Di Tommaso M and Cipone M. Use of the vertebral heart score in coughing dogs with chronic degenerative mitral valve disease. J Vet Med Sci 71: 9-13, 2009. Haas M and McBrayer DG. Na-K-Cl cotransport in nystatin-treated tracheal cells: regulation by isoproterenol, apical UTP, and [Cl]i. Am J Physiol 266: C1440-52, 1994. Haggstrom J, Boswood A, O''Grady M, Jons O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacevic A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Ronn-Landbo M, Wess G, Eggertsdottir AV, O''Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A and DiFruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 22: 1124-35, 2008. Haggstrom J, Duelund Pedersen H and Kvart C. New insights into degenerative mitral valve disease in dogs. Vet Clin North Am Small Anim Pract 34: 1209-26, vii-viii, 2004. Hamlin RL and Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med 12: 93-5, 1998. Hyun C. Mitral valve prolapse in Cavalier King Charles spaniel: a review and case study. J Vet Sci 6: 67-73, 2005. Ibsen H, Egan B, Osterziel K, Vander A and Julius S. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 5: I184-91, 1983. Israili ZH and Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117: 234-42, 1992. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P and Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16: 564-72, 1990. Kanno N, Kuse H, Kawasaki M, Hara A, Kano R and Sasaki Y. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci 69: 373-7, 2007. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, Brozena S, Brodsky M, Kirlin P, Shanes J and et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 85: 942-9, 1992. Kvart C, Haggstrom J, Pedersen HD, Hansson K, Eriksson A, Jarvinen AK, Tidholm A, Bsenko K, Ahlgren E, Ilves M, Ablad B, Falk T, Bjerkfas E, Gundler S, Lord P, Wegeland G, Adolfsson E and Corfitzen J. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 16: 80-8, 2002. Lane IF, Shaw DH, Burton SA and Donald AW. Quantitative urinalysis in healthy Beagle puppies from 9 to 27 weeks of age. Am J Vet Res 61: 577-81, 2000. Lefebvre HP, Brown SA, Chetboul V, King JN, Pouchelon JL and Toutain PL. Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des 13: 1347-61, 2007. Levine TB, Franciosa JA and Cohn JN. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62: 35-41, 1980. Lombard CW, Jons O and Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 42: 249-61, 2006. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM and Seed P. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 76: 223-31, 1996. Maruyama M, Takamura M, Takata S, Murai H, Usui S, Furusho H, Sakagami S, Yuasa T, Shimakura A and Kaneko S. Effect of pimobendan on cardiopulmonary baroreflex control of sympathetic nerve activity in healthy young men. Auton Neurosci 122: 100-6, 2005. McAlister FA, Ezekowitz J, Tonelli M and Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-9, 2004. Ohte N, Cheng CP, Suzuki M and Little WC. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 282: 23-31, 1997. Ouellet M, Belanger MC, Difruscia R and Beauchamp G. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med 23: 258-63, 2009. Oyama MA. A QUEST begins. J Vet Intern Med 22: 1076-8, 2008. Oyama MA, Sisson DD, Bulmer BJ and Constable PD. Echocardiographic estimation of mean left atrial pressure in a canine model of acute mitral valve insufficiency. J Vet Intern Med 18: 667-72, 2004. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 22: 119A-126A, 1993. Pedersen HD, Kristensen BO, Lorentzen KA, Koch J, Jensen AL and Flagstad A. Mitral valve prolapse in 3-year-old healthy Cavalier King Charles Spaniels. An echocardiographic study. Can J Vet Res 59: 294-8, 1995. Pedersen HD, Lorentzen KA and Kristensen BO. Echocardiographic mitral valve prolapse in cavalier King Charles spaniels: epidemiology and prognostic significance for regurgitation. Vet Rec 144: 315-20, 1999. Perreault CL, Shannon RP, Komamura K, Vatner SF and Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 89: 932-8, 1992. Pouchelon JL, Jamet N, Gouni V, Tissier R, Serres F, Carlos Sampedrano C, Castaignet M, Lefebvre HP and Chetboul V. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 22: 905-14, 2008. Remme WJ, Krayenbuhl HP, Baumann G, Frick MH, Haehl M, Nehmiz G and Baiker W. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Eur Heart J 15: 947-56, 1994. Schneider P, Guttner J, Eckenfels A, Heinzel G, von Nicolai H, Trieb G and Lehmann H. Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs. Exp Toxicol Pathol 49: 217-24, 1997. Serres F, Chetboul V, Tissier R, Poujol L, Gouni V, Carlos Sampedrano C and Pouchelon JL. Comparison of 3 ultrasound methods for quantifying left ventricular systolic function: correlation with disease severity and prognostic value in dogs with mitral valve disease. J Vet Intern Med 22: 566-77, 2008. Serres F, Chetboul V, Tissier R, Sampedrano CC, Gouni V, Nicolle AP and Pouchelon JL. Chordae tendineae rupture in dogs with degenerative mitral valve disease: prevalence, survival, and prognostic factors (114 cases, 2001-2006). J Vet Intern Med 21: 258-64, 2007. Smith PJ, French AT, Van Israel N, Smith SG, Swift ST, Lee AJ, Corcoran BM and Dukes-McEwan J. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 46: 121-30, 2005. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG and Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 65: 1257-64, 1980. Textor SC, Bravo EL, Fouad FM and Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73: 719-25, 1982. Timek TA, Lai DT, Dagum P, Liang D, Daughters GT, Ingels NB, Jr. and Miller DC. Mitral leaflet remodeling in dilated cardiomyopathy. Circulation 114: I518-23, 2006. Toutain PL and Lefebvre HP. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther 27: 515-25, 2004. Toyohira Y, Kubo T, Watanabe M, Uezono Y, Ueno S, Shinkai K, Tsutsui M, Izumi F and Yanagihara N. Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: reduction of catecholamine secretion and synthesis in adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol 371: 107-13, 2005. Vaughan DE and Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res 28: 159-65, 1994. Verdouw PD, Hartog JM, Duncker DJ, Roth W and Saxena PR. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 126: 21-30, 1986. Warren SE and O''Connor DT. Hyperkalemia resulting from captopril administration. Jama 244: 2551-2, 1980.
摘要: 摘要 二尖瓣病變是犬隻最常見的後天性心臟病之一。Pimobendan (PIMO)與ACE inhibitor (ACEi)類藥物為治療鬱血性心衰竭中最普遍使用的藥物。本實驗的目的為比較二尖瓣逆流犬隻投與PIMO 、Enalapril以及這兩種藥物合併使用時對於犬隻心臟功能、心臟輪廓大小以及肺水腫程度、血液動力學等各方面的影響。本研究共有18例具有二尖瓣逆流的犬隻為實驗組, 6例健康犬隻列為對照組。將實驗組以隨機的方式分成三組分別投與PIMO、Enalapril和此兩種藥物合併使用。在投藥前、投藥後第7天、第28天以及第56天監測其理學檢查、心臟超音波學檢查、胸腔放射學檢查及血液及血清生化學檢查等各項數值的變化。同時以心臟都卜勒超音波測量犬隻二尖瓣逆流的速度變化。結果投與PIMO的犬隻在各時期二尖瓣逆流流速皆出現上升的情形(p<0.05)。投與Enalapril的犬隻則出現血液中Creatinine及鉀離子濃度上升的情形(p<0.05)。兩種藥物合併使用的犬隻則是在肺水腫的程度獲得顯著的改善(p<0.05)。將實驗組與對照組之二尖瓣以及主動脈瓣流速作比較後發現,其實驗組的二尖瓣以及主動脈瓣流速普遍較對照組高(p<0.05)。本實驗結果顯示,於心衰竭犬隻給予PIMO可能會令二尖瓣逆流的程度加重,而將PIMO與ACEi類藥物合併使用則可能會減低PIMO對二尖瓣逆流所造成的不良影響進而對肺水腫的程度有所改善。關於合併用法是否能有效的降低二尖瓣逆流的程度以及是否會造成如低血壓等副作用,仍需要對不同劑量反應所造成的影響進行評估。
Abstract Mitral valve disease (MVD) is the most common acquired cardiac disease in dogs. Pimobendan (PIMO) and ACE inhibitor (ACEi) are frequently used for congestive heart failure. The aim of the study was to monitor the changes of the cardiac function, dimensions of the cardiac silhouette in thoracic radiograms, degree of pulmonary edema and hemodynamic effects in dogs with mitral valve regurgitation (MR) after the treatment of PIMO, enalapril, and combined use of two drugs. Eighteen dogs with mild-moderate MR and six healthy dogs were recruited in this study. The dogs with MR were randomly allocated into 3 groups and monitored at the day 0, 7, 28 and 56. Doppler echocardiography showed that the MR velocity had increasing tendency in the PIMO group (p<0.05). Haematology and blood biochemistry revealed creatinine and potassium concentration had increasing tendency in the enalapril group (p<0.05). The degree of pulmonary edema had decreasing tendency in the combined group (p<0.05). However, the velocity of mitral and the aorta valve measured from the dogs with MR were higher than that from the healthy dogs (p<0.05). Above results indicates that PIMO increase mitral valve regurgitation in the dogs with heart failure. The combined use of PIMO and enalapril may decrease the adverse effect of PIMO and comfort the pulmonary edema severity. Additional studies are required to investigate the adverse effect on blood pressure and changes of mitral valve regurgitation in different dose response.
URI: http://hdl.handle.net/11455/13888
其他識別: U0005-2108200905053100
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2108200905053100
顯示於類別:獸醫學系所

文件中的檔案:
沒有與此文件相關的檔案。


在 DSpace 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。